Effect of Probiotic and Zinc Supplementations on the Clinical Outcome in Pediatric Patients with Ventriculitis
NCT ID: NCT06151392
Last Updated: 2025-02-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
140 participants
INTERVENTIONAL
2023-07-01
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study objective is to detect the efficacy of probiotics and zinc when taken simultaneously with antibiotic treatment as immunomodulatory in increasing the recovery rate in pediatric population affected with ventriculitis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Probiotics in the Treatment of Acute Gastroenteritis in Children
NCT03539913
Pilot of a Prebiotic and Probiotic Trial in Young Infants With Severe Acute Malnutrition
NCT03666572
Zinc and/or Probiotic Supplementation of Rotavirus and Oral Polio Virus Vaccines
NCT01616693
Investigating the Bactericidal Effect of Probiotics on Chromogenic Bacteria in Children An In Vivo and In Vitro Study
NCT06834815
COMPARISON OF ZINC AND PROBIOTICS ON NEONATES WITH INDIRECT HYPERBILIRUBINEMIA UNDERGOING PHOTOTHERAPY
NCT07102836
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Setting:The study will be conducted at the Neurosurgery department with the Ain Shams University Hospitals.
Pediatric Patients admitted to the neurosurgery department according to the inclusion criteria will be enrolled in the study and divided into four groups using simple randomization method.
Group A: Patients administer probiotics along with the standard care of therapy for a duration of 14 days.
Lacteol fort ® Sachets manufactured by Rameda contains Lactobacillus LB corresponding to lactobacillus delbruekii and lactobacillus fermentum 10 billion units per sachet.
Dose: 5 billion units once or twice daily. Dosing and duration regimens were guided from Lexicomp Online, Pediatric and Neonatal Lexi-Drugs. https://online.lexi.com. Also, from other studies using probiotics.
Group B: Patients administering zinc supplementation along with the standard care of therapy for the duration of 14 days.
Zn origin® 10 mg/5 mL syrup is manufactured by Egyptian Group for Pharmaceutical Industries. For Origin International Pharma, every 100 mL syrup constituted of 0.8793 g Zn sulfate heptahydrate which contained 0.2 g elemental Zn. Dose:
Infants \<3 months: 250 mcg elemental zinc/kg/day. Infants ≥3 months: 100 mcg elemental zinc/kg/day. Dosing and duration regimens were guided from Lexicomp Online, Pediatric and Neonatal Lexi-Drugs. https://online.lexi.com. Also, from other studies using zinc.
Group C: Patients administering probiotics and zinc supplementation along with the standard care of therapy for the duration of 14 days.
Group D: Patients administer only the standard care of therapy (control group). Patient data collection
A. Demographic data:
Including age, sex, weight, height, body mass index.
B. Medication and medical history:
Including patient's medical history, past surgical history, family medical history, and medications the patient is taking or may have recently stopped taking.
A patient's medical history may also include information about allergies, surgeries, immunizations, health habits, such as feeding and sleeping habits.
C. Laboratory examinations The following laboratory data to be measured at baseline and after duration of treatment period of 14 days.
1. CSF culture. Cultures and sensitivity tests from the suspected site of infection were withdrawn from all patients at baseline. Antibiotic susceptibility was carried out using agar diffusion and broth dilution method according to clinical and laboratory standards institute (CLSI) guidelines.
2. CSF chemistry (protein and glucose level). Studies showed that CSF composition comparison had higher leukocyte count in ventriculitis cases. Also, a significantly higher CSF protein and lower CSF glucose value in ventriculitis cases.
3. C-reactive protein (CRP). measured by an immunonephelometric method. CRP is considered an acute phase protein which is synthesized in liver in the presence of infection, it is usually effective in the follow-up of the infection severity.
4. Procalcitonin biomarker. measured by an immunoluminometric assay. It is a 116-amino acid prohormone and is the precursor of hormone calcitonin produced by thyroid gland under normal conditions, the serum concentration of PCT increases significantly during infections. It is secreted from the liver and circulating macrophages in response to infections and could be used for the diagnosis and follow-up.
5. Complete blood picture (CBC) including TLC, RBC, Monocytes and Macrophages.
6. ESR
7. Interleukin-6
D. Signs and symptoms
Follow up the patient signs and symptoms of ventriculitis from hospital admission and during duration of treatment. The Centers for Disease Control and Prevention's National Healthcare Safety Network (CDC/NHSN) definition of healthcare-associated ventriculitis or meningitis includes at least 1 of the following criteria :
Organism cultured from CSF. At least 2 of the following symptoms with no other recognized cause in patients aged \>1 year: fever \>38°C or headache, meningeal signs, or cranial nerve signs, or at least 2 of the following symptoms with no other recognized cause in patients aged ≤1 year: fever \>38°C or hypothermia a \<36°C, apnea, bradycardia, or irritability and at least 1 of the following:
* Increased white cells, elevated protein, and decreased glucose in CSF
* Organisms seen on Gram stain of CSF
* Organisms cultured from blood
* Positive nonculture diagnostic laboratory test from CSF, blood, or urine.
E. Safety and Tolerability Evaluation of the safety of probiotic supplementation and zinc in pediatric patients with ventriculitis in terms of side effects and adverse drug events.
F. Patients' follow-up Patients will be followed up during their hospital stay through laboratory examination at baseline and at end of study (14 days).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Probiotic group
probiotic will be administered to this group of pediatric patients with ventriculitis
Probiotic Formula
probiotic will be administered to pediatric patients with ventriculitis to study their possible effect in treatment
Zinc group
Zinc will be administered to this group of pediatric patients with ventriculitis
Zinc
Zinc will be administered to pediatric patients with ventriculitis to study their possible effect in treatment
Probiotic and Zinc group
probiotic and Zinc will be administered to this group of pediatric patients with ventriculitis
Probiotic Formula
probiotic will be administered to pediatric patients with ventriculitis to study their possible effect in treatment
Zinc
Zinc will be administered to pediatric patients with ventriculitis to study their possible effect in treatment
Control group
interventional drug will not be administered to this group of pediatric patients with ventriculitis
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Probiotic Formula
probiotic will be administered to pediatric patients with ventriculitis to study their possible effect in treatment
Zinc
Zinc will be administered to pediatric patients with ventriculitis to study their possible effect in treatment
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients with allergy to zinc.
* Patients with allergy to probiotics.
1 Month
4 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ain shams university
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
195
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.